Roots Analysis provided evidence-based risk profiling for a program focused on SEMA3A pharmacological inhibition. The engagement helped the client understand the scientific, developmental, and competitive risks associated with the therapeutic approach.
The challenge
Early-stage therapeutic programs require a clear understanding of biological rationale, evidence maturity, competitive activity, and development risk. The client needed a structured assessment to support internal decision-making.
The approach
Roots Analysis reviewed scientific literature, clinical and preclinical evidence, competitive activity, and relevant development considerations. The team synthesized the findings into a risk-focused assessment of the SEMA3A inhibition approach.
The outcome
The client gained a clearer view of the opportunity, evidence gaps, and key risks. The insights supported more informed development and portfolio decisions.
Key takeaway
Early risk profiling helps organizations distinguish promising scientific concepts from opportunities that require stronger validation.
Explore the full SEMA3A risk profiling case study - https://rootsanalysis.com/case-studies/evidence-based-risk-profiling-for-sema3a-pharmacological-inhibition